nodes	percent_of_prediction	percent_of_DWPC	metapath
Moclobemide—CYP1A2—Clobetasol propionate—psoriasis	0.156	0.232	CbGbCtD
Moclobemide—CYP1A2—Methoxsalen—psoriasis	0.0819	0.122	CbGbCtD
Moclobemide—CYP2D6—Hydroxyurea—psoriasis	0.0738	0.11	CbGbCtD
Moclobemide—CYP2C19—Cholecalciferol—psoriasis	0.0588	0.0877	CbGbCtD
Moclobemide—CYP2C9—Cholecalciferol—psoriasis	0.0489	0.0729	CbGbCtD
Moclobemide—CYP2D6—Cholecalciferol—psoriasis	0.0447	0.0666	CbGbCtD
Moclobemide—CYP2C19—Prednisone—psoriasis	0.0408	0.0608	CbGbCtD
Moclobemide—CYP2C19—Cyclosporine—psoriasis	0.0387	0.0576	CbGbCtD
Moclobemide—CYP2C9—Cyclosporine—psoriasis	0.0321	0.0479	CbGbCtD
Moclobemide—CYP2D6—Cyclosporine—psoriasis	0.0294	0.0438	CbGbCtD
Moclobemide—CYP2C19—Dexamethasone—psoriasis	0.0255	0.0379	CbGbCtD
Moclobemide—CYP2C9—Dexamethasone—psoriasis	0.0212	0.0315	CbGbCtD
Moclobemide—CYP2D6—Dexamethasone—psoriasis	0.0194	0.0288	CbGbCtD
Moclobemide—Bezafibrate—PPARG—psoriasis	0.00188	1	CrCbGaD
Moclobemide—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.0015	0.0678	CbGpPWpGaD
Moclobemide—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.00138	0.0624	CbGpPWpGaD
Moclobemide—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00136	0.0619	CbGpPWpGaD
Moclobemide—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.00128	0.0582	CbGpPWpGaD
Moclobemide—MAOB—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00105	0.0477	CbGpPWpGaD
Moclobemide—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.000927	0.042	CbGpPWpGaD
Moclobemide—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000852	0.0387	CbGpPWpGaD
Moclobemide—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000845	0.0383	CbGpPWpGaD
Moclobemide—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.000722	0.0328	CbGpPWpGaD
Moclobemide—MAOA—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000659	0.0299	CbGpPWpGaD
Moclobemide—MAOB—Biological oxidations—CYP2S1—psoriasis	0.000558	0.0253	CbGpPWpGaD
Moclobemide—MAOB—Tryptophan metabolism—CAT—psoriasis	0.000481	0.0218	CbGpPWpGaD
Moclobemide—MAOA—Oxidative Stress—CAT—psoriasis	0.000425	0.0193	CbGpPWpGaD
Moclobemide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000385	0.0175	CbGpPWpGaD
Moclobemide—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00038	0.0172	CbGpPWpGaD
Moclobemide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000354	0.0161	CbGpPWpGaD
Moclobemide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000351	0.0159	CbGpPWpGaD
Moclobemide—MAOA—Biological oxidations—CYP2S1—psoriasis	0.00035	0.0159	CbGpPWpGaD
Moclobemide—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000349	0.0158	CbGpPWpGaD
Moclobemide—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000346	0.0157	CbGpPWpGaD
Moclobemide—MAOA—Melatonin metabolism and effects—APOE—psoriasis	0.000339	0.0154	CbGpPWpGaD
Moclobemide—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000312	0.0142	CbGpPWpGaD
Moclobemide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.0003	0.0136	CbGpPWpGaD
Moclobemide—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000296	0.0134	CbGpPWpGaD
Moclobemide—Anxiety—Hydrocortisone—psoriasis	0.000292	0.000957	CcSEcCtD
Moclobemide—Syncope—Triamcinolone—psoriasis	0.000291	0.000953	CcSEcCtD
Moclobemide—Discomfort—Hydrocortisone—psoriasis	0.000289	0.000949	CcSEcCtD
Moclobemide—Hypotension—Mycophenolate mofetil—psoriasis	0.000288	0.000944	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.000288	0.000944	CcSEcCtD
Moclobemide—Dysuria—Methotrexate—psoriasis	0.000287	0.000941	CcSEcCtD
Moclobemide—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000287	0.013	CbGpPWpGaD
Moclobemide—Insomnia—Cyclosporine—psoriasis	0.000286	0.000937	CcSEcCtD
Moclobemide—Loss of consciousness—Triamcinolone—psoriasis	0.000285	0.000934	CcSEcCtD
Moclobemide—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000284	0.0129	CbGpPWpGaD
Moclobemide—Paraesthesia—Cyclosporine—psoriasis	0.000284	0.00093	CcSEcCtD
Moclobemide—Shock—Prednisolone—psoriasis	0.000283	0.000927	CcSEcCtD
Moclobemide—Dyspnoea—Cyclosporine—psoriasis	0.000282	0.000924	CcSEcCtD
Moclobemide—Somnolence—Cyclosporine—psoriasis	0.000281	0.000921	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.000281	0.000921	CcSEcCtD
Moclobemide—Tachycardia—Prednisolone—psoriasis	0.000281	0.00092	CcSEcCtD
Moclobemide—Asthenia—Mycophenolic acid—psoriasis	0.00028	0.000919	CcSEcCtD
Moclobemide—Hypertension—Triamcinolone—psoriasis	0.00028	0.000917	CcSEcCtD
Moclobemide—Insomnia—Mycophenolate mofetil—psoriasis	0.000279	0.000914	CcSEcCtD
Moclobemide—Dyspepsia—Cyclosporine—psoriasis	0.000278	0.000912	CcSEcCtD
Moclobemide—Hyperhidrosis—Prednisolone—psoriasis	0.000278	0.000911	CcSEcCtD
Moclobemide—Nausea—Hydroxyurea—psoriasis	0.000277	0.000908	CcSEcCtD
Moclobemide—Paraesthesia—Mycophenolate mofetil—psoriasis	0.000277	0.000907	CcSEcCtD
Moclobemide—Pruritus—Mycophenolic acid—psoriasis	0.000276	0.000906	CcSEcCtD
Moclobemide—Shock—Hydrocortisone—psoriasis	0.000276	0.000906	CcSEcCtD
Moclobemide—Myalgia—Triamcinolone—psoriasis	0.000276	0.000904	CcSEcCtD
Moclobemide—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000275	0.000901	CcSEcCtD
Moclobemide—Decreased appetite—Cyclosporine—psoriasis	0.000275	0.0009	CcSEcCtD
Moclobemide—Tachycardia—Hydrocortisone—psoriasis	0.000274	0.000899	CcSEcCtD
Moclobemide—Somnolence—Mycophenolate mofetil—psoriasis	0.000274	0.000898	CcSEcCtD
Moclobemide—Drowsiness—Methotrexate—psoriasis	0.000274	0.000898	CcSEcCtD
Moclobemide—Flushing—Prednisone—psoriasis	0.000273	0.000895	CcSEcCtD
Moclobemide—Ill-defined disorder—Betamethasone—psoriasis	0.000273	0.000894	CcSEcCtD
Moclobemide—Ill-defined disorder—Dexamethasone—psoriasis	0.000273	0.000894	CcSEcCtD
Moclobemide—Discomfort—Triamcinolone—psoriasis	0.000273	0.000893	CcSEcCtD
Moclobemide—Fatigue—Cyclosporine—psoriasis	0.000272	0.000893	CcSEcCtD
Moclobemide—Hyperhidrosis—Hydrocortisone—psoriasis	0.000271	0.00089	CcSEcCtD
Moclobemide—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000271	0.00089	CcSEcCtD
Moclobemide—Constipation—Cyclosporine—psoriasis	0.00027	0.000886	CcSEcCtD
Moclobemide—Dry mouth—Triamcinolone—psoriasis	0.00027	0.000884	CcSEcCtD
Moclobemide—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000268	0.000878	CcSEcCtD
Moclobemide—Diarrhoea—Mycophenolic acid—psoriasis	0.000267	0.000876	CcSEcCtD
Moclobemide—Stomatitis—Methotrexate—psoriasis	0.000267	0.000875	CcSEcCtD
Moclobemide—Conjunctivitis—Methotrexate—psoriasis	0.000266	0.000872	CcSEcCtD
Moclobemide—Malaise—Dexamethasone—psoriasis	0.000265	0.000869	CcSEcCtD
Moclobemide—Malaise—Betamethasone—psoriasis	0.000265	0.000869	CcSEcCtD
Moclobemide—Syncope—Betamethasone—psoriasis	0.000264	0.000864	CcSEcCtD
Moclobemide—Syncope—Dexamethasone—psoriasis	0.000264	0.000864	CcSEcCtD
Moclobemide—Constipation—Mycophenolate mofetil—psoriasis	0.000264	0.000864	CcSEcCtD
Moclobemide—Sweating—Methotrexate—psoriasis	0.000262	0.00086	CcSEcCtD
Moclobemide—Hypotension—Hydrocortisone—psoriasis	0.000262	0.00086	CcSEcCtD
Moclobemide—Feeling abnormal—Cyclosporine—psoriasis	0.00026	0.000854	CcSEcCtD
Moclobemide—Shock—Triamcinolone—psoriasis	0.00026	0.000853	CcSEcCtD
Moclobemide—Insomnia—Prednisolone—psoriasis	0.00026	0.000853	CcSEcCtD
Moclobemide—Gastrointestinal pain—Cyclosporine—psoriasis	0.000258	0.000847	CcSEcCtD
Moclobemide—Loss of consciousness—Betamethasone—psoriasis	0.000258	0.000847	CcSEcCtD
Moclobemide—Loss of consciousness—Dexamethasone—psoriasis	0.000258	0.000847	CcSEcCtD
Moclobemide—Dizziness—Mycophenolic acid—psoriasis	0.000258	0.000847	CcSEcCtD
Moclobemide—Paraesthesia—Prednisolone—psoriasis	0.000258	0.000846	CcSEcCtD
Moclobemide—Tachycardia—Triamcinolone—psoriasis	0.000258	0.000846	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000256	0.000839	CcSEcCtD
Moclobemide—Hyperhidrosis—Triamcinolone—psoriasis	0.000256	0.000838	CcSEcCtD
Moclobemide—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000254	0.000833	CcSEcCtD
Moclobemide—Insomnia—Hydrocortisone—psoriasis	0.000254	0.000833	CcSEcCtD
Moclobemide—Hypertension—Dexamethasone—psoriasis	0.000254	0.000832	CcSEcCtD
Moclobemide—Hypertension—Betamethasone—psoriasis	0.000254	0.000832	CcSEcCtD
Moclobemide—Paraesthesia—Hydrocortisone—psoriasis	0.000252	0.000827	CcSEcCtD
Moclobemide—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000252	0.000826	CcSEcCtD
Moclobemide—Urticaria—Cyclosporine—psoriasis	0.000251	0.000823	CcSEcCtD
Moclobemide—Myalgia—Betamethasone—psoriasis	0.00025	0.00082	CcSEcCtD
Moclobemide—Myalgia—Dexamethasone—psoriasis	0.00025	0.00082	CcSEcCtD
Moclobemide—Abdominal pain—Cyclosporine—psoriasis	0.00025	0.000819	CcSEcCtD
Moclobemide—Anxiety—Dexamethasone—psoriasis	0.000249	0.000818	CcSEcCtD
Moclobemide—Anxiety—Betamethasone—psoriasis	0.000249	0.000818	CcSEcCtD
Moclobemide—Vomiting—Mycophenolic acid—psoriasis	0.000248	0.000814	CcSEcCtD
Moclobemide—Discomfort—Dexamethasone—psoriasis	0.000247	0.000811	CcSEcCtD
Moclobemide—Discomfort—Betamethasone—psoriasis	0.000247	0.000811	CcSEcCtD
Moclobemide—Dyspepsia—Hydrocortisone—psoriasis	0.000247	0.00081	CcSEcCtD
Moclobemide—Rash—Mycophenolic acid—psoriasis	0.000246	0.000807	CcSEcCtD
Moclobemide—Dermatitis—Mycophenolic acid—psoriasis	0.000246	0.000807	CcSEcCtD
Moclobemide—Urticaria—Mycophenolate mofetil—psoriasis	0.000245	0.000803	CcSEcCtD
Moclobemide—Headache—Mycophenolic acid—psoriasis	0.000245	0.000802	CcSEcCtD
Moclobemide—Decreased appetite—Hydrocortisone—psoriasis	0.000244	0.0008	CcSEcCtD
Moclobemide—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000244	0.000799	CcSEcCtD
Moclobemide—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000243	0.011	CbGpPWpGaD
Moclobemide—Fatigue—Hydrocortisone—psoriasis	0.000242	0.000794	CcSEcCtD
Moclobemide—Vision blurred—Prednisone—psoriasis	0.000241	0.000791	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000241	0.00079	CcSEcCtD
Moclobemide—Insomnia—Triamcinolone—psoriasis	0.000239	0.000784	CcSEcCtD
Moclobemide—Ill-defined disorder—Prednisone—psoriasis	0.000238	0.000779	CcSEcCtD
Moclobemide—Paraesthesia—Triamcinolone—psoriasis	0.000237	0.000778	CcSEcCtD
Moclobemide—Feeling abnormal—Prednisolone—psoriasis	0.000237	0.000777	CcSEcCtD
Moclobemide—Visual impairment—Methotrexate—psoriasis	0.000237	0.000777	CcSEcCtD
Moclobemide—Shock—Dexamethasone—psoriasis	0.000236	0.000774	CcSEcCtD
Moclobemide—Shock—Betamethasone—psoriasis	0.000236	0.000774	CcSEcCtD
Moclobemide—Dyspnoea—Triamcinolone—psoriasis	0.000236	0.000773	CcSEcCtD
Moclobemide—Agitation—Prednisone—psoriasis	0.000235	0.000771	CcSEcCtD
Moclobemide—Tachycardia—Betamethasone—psoriasis	0.000234	0.000768	CcSEcCtD
Moclobemide—Tachycardia—Dexamethasone—psoriasis	0.000234	0.000768	CcSEcCtD
Moclobemide—Dyspepsia—Triamcinolone—psoriasis	0.000233	0.000763	CcSEcCtD
Moclobemide—Nausea—Mycophenolic acid—psoriasis	0.000232	0.000761	CcSEcCtD
Moclobemide—Hyperhidrosis—Dexamethasone—psoriasis	0.000232	0.00076	CcSEcCtD
Moclobemide—Hyperhidrosis—Betamethasone—psoriasis	0.000232	0.00076	CcSEcCtD
Moclobemide—Feeling abnormal—Hydrocortisone—psoriasis	0.000231	0.000759	CcSEcCtD
Moclobemide—Malaise—Prednisone—psoriasis	0.000231	0.000757	CcSEcCtD
Moclobemide—Gastrointestinal pain—Hydrocortisone—psoriasis	0.00023	0.000753	CcSEcCtD
Moclobemide—Syncope—Prednisone—psoriasis	0.00023	0.000753	CcSEcCtD
Moclobemide—Tinnitus—Methotrexate—psoriasis	0.000229	0.000751	CcSEcCtD
Moclobemide—Urticaria—Prednisolone—psoriasis	0.000228	0.000749	CcSEcCtD
Moclobemide—Fatigue—Triamcinolone—psoriasis	0.000228	0.000747	CcSEcCtD
Moclobemide—Asthenia—Cyclosporine—psoriasis	0.000227	0.000743	CcSEcCtD
Moclobemide—Loss of consciousness—Prednisone—psoriasis	0.000225	0.000738	CcSEcCtD
Moclobemide—Hypotension—Dexamethasone—psoriasis	0.000224	0.000735	CcSEcCtD
Moclobemide—Hypotension—Betamethasone—psoriasis	0.000224	0.000735	CcSEcCtD
Moclobemide—Pruritus—Cyclosporine—psoriasis	0.000224	0.000733	CcSEcCtD
Moclobemide—Urticaria—Hydrocortisone—psoriasis	0.000223	0.000731	CcSEcCtD
Moclobemide—Abdominal pain—Hydrocortisone—psoriasis	0.000222	0.000728	CcSEcCtD
Moclobemide—Asthenia—Mycophenolate mofetil—psoriasis	0.000221	0.000725	CcSEcCtD
Moclobemide—Hypertension—Prednisone—psoriasis	0.000221	0.000725	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000219	0.000717	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000219	0.000717	CcSEcCtD
Moclobemide—Pruritus—Mycophenolate mofetil—psoriasis	0.000218	0.000715	CcSEcCtD
Moclobemide—Myalgia—Prednisone—psoriasis	0.000218	0.000715	CcSEcCtD
Moclobemide—Feeling abnormal—Triamcinolone—psoriasis	0.000218	0.000714	CcSEcCtD
Moclobemide—MAOA—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000217	0.00986	CbGpPWpGaD
Moclobemide—Anxiety—Prednisone—psoriasis	0.000217	0.000712	CcSEcCtD
Moclobemide—Insomnia—Dexamethasone—psoriasis	0.000217	0.000711	CcSEcCtD
Moclobemide—Insomnia—Betamethasone—psoriasis	0.000217	0.000711	CcSEcCtD
Moclobemide—Diarrhoea—Cyclosporine—psoriasis	0.000216	0.000709	CcSEcCtD
Moclobemide—Paraesthesia—Dexamethasone—psoriasis	0.000215	0.000706	CcSEcCtD
Moclobemide—Paraesthesia—Betamethasone—psoriasis	0.000215	0.000706	CcSEcCtD
Moclobemide—Discomfort—Prednisone—psoriasis	0.000215	0.000706	CcSEcCtD
Moclobemide—Dyspepsia—Dexamethasone—psoriasis	0.000211	0.000692	CcSEcCtD
Moclobemide—Dyspepsia—Betamethasone—psoriasis	0.000211	0.000692	CcSEcCtD
Moclobemide—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000211	0.000691	CcSEcCtD
Moclobemide—Urticaria—Triamcinolone—psoriasis	0.00021	0.000689	CcSEcCtD
Moclobemide—Dysgeusia—Methotrexate—psoriasis	0.00021	0.000687	CcSEcCtD
Moclobemide—Dizziness—Cyclosporine—psoriasis	0.000209	0.000685	CcSEcCtD
Moclobemide—Decreased appetite—Dexamethasone—psoriasis	0.000209	0.000684	CcSEcCtD
Moclobemide—Decreased appetite—Betamethasone—psoriasis	0.000209	0.000684	CcSEcCtD
Moclobemide—Fatigue—Betamethasone—psoriasis	0.000207	0.000678	CcSEcCtD
Moclobemide—Fatigue—Dexamethasone—psoriasis	0.000207	0.000678	CcSEcCtD
Moclobemide—Shock—Prednisone—psoriasis	0.000206	0.000674	CcSEcCtD
Moclobemide—Tachycardia—Prednisone—psoriasis	0.000204	0.000669	CcSEcCtD
Moclobemide—Dizziness—Mycophenolate mofetil—psoriasis	0.000204	0.000668	CcSEcCtD
Moclobemide—Hyperhidrosis—Prednisone—psoriasis	0.000202	0.000662	CcSEcCtD
Moclobemide—MAOA—Melatonin metabolism and effects—NFKB1—psoriasis	0.000202	0.00916	CbGpPWpGaD
Moclobemide—Vision blurred—Methotrexate—psoriasis	0.000202	0.000661	CcSEcCtD
Moclobemide—Asthenia—Hydrocortisone—psoriasis	0.000201	0.000661	CcSEcCtD
Moclobemide—Vomiting—Cyclosporine—psoriasis	0.000201	0.000659	CcSEcCtD
Moclobemide—Rash—Cyclosporine—psoriasis	0.000199	0.000653	CcSEcCtD
Moclobemide—Dermatitis—Cyclosporine—psoriasis	0.000199	0.000653	CcSEcCtD
Moclobemide—Pruritus—Hydrocortisone—psoriasis	0.000199	0.000651	CcSEcCtD
Moclobemide—Ill-defined disorder—Methotrexate—psoriasis	0.000199	0.000651	CcSEcCtD
Moclobemide—Headache—Cyclosporine—psoriasis	0.000198	0.000649	CcSEcCtD
Moclobemide—Feeling abnormal—Betamethasone—psoriasis	0.000198	0.000648	CcSEcCtD
Moclobemide—Feeling abnormal—Dexamethasone—psoriasis	0.000198	0.000648	CcSEcCtD
Moclobemide—MAOA—Oxidative Stress—NFKB1—psoriasis	0.000196	0.00891	CbGpPWpGaD
Moclobemide—Gastrointestinal pain—Dexamethasone—psoriasis	0.000196	0.000643	CcSEcCtD
Moclobemide—Gastrointestinal pain—Betamethasone—psoriasis	0.000196	0.000643	CcSEcCtD
Moclobemide—Vomiting—Mycophenolate mofetil—psoriasis	0.000196	0.000643	CcSEcCtD
Moclobemide—Rash—Mycophenolate mofetil—psoriasis	0.000194	0.000637	CcSEcCtD
Moclobemide—Dermatitis—Mycophenolate mofetil—psoriasis	0.000194	0.000637	CcSEcCtD
Moclobemide—Headache—Mycophenolate mofetil—psoriasis	0.000193	0.000633	CcSEcCtD
Moclobemide—Malaise—Methotrexate—psoriasis	0.000193	0.000633	CcSEcCtD
Moclobemide—Diarrhoea—Hydrocortisone—psoriasis	0.000192	0.00063	CcSEcCtD
Moclobemide—Urticaria—Betamethasone—psoriasis	0.000191	0.000625	CcSEcCtD
Moclobemide—Urticaria—Dexamethasone—psoriasis	0.000191	0.000625	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Prednisone—psoriasis	0.00019	0.000624	CcSEcCtD
Moclobemide—Dizziness—Prednisolone—psoriasis	0.00019	0.000623	CcSEcCtD
Moclobemide—Asthenia—Triamcinolone—psoriasis	0.00019	0.000622	CcSEcCtD
Moclobemide—Abdominal pain—Betamethasone—psoriasis	0.00019	0.000622	CcSEcCtD
Moclobemide—Abdominal pain—Dexamethasone—psoriasis	0.00019	0.000622	CcSEcCtD
Moclobemide—Insomnia—Prednisone—psoriasis	0.000189	0.00062	CcSEcCtD
Moclobemide—Nausea—Cyclosporine—psoriasis	0.000188	0.000615	CcSEcCtD
Moclobemide—Paraesthesia—Prednisone—psoriasis	0.000188	0.000615	CcSEcCtD
Moclobemide—Pruritus—Triamcinolone—psoriasis	0.000187	0.000613	CcSEcCtD
Moclobemide—Dizziness—Hydrocortisone—psoriasis	0.000186	0.000609	CcSEcCtD
Moclobemide—Dyspepsia—Prednisone—psoriasis	0.000184	0.000603	CcSEcCtD
Moclobemide—Nausea—Mycophenolate mofetil—psoriasis	0.000183	0.0006	CcSEcCtD
Moclobemide—Chest pain—Methotrexate—psoriasis	0.000182	0.000597	CcSEcCtD
Moclobemide—Myalgia—Methotrexate—psoriasis	0.000182	0.000597	CcSEcCtD
Moclobemide—Decreased appetite—Prednisone—psoriasis	0.000182	0.000595	CcSEcCtD
Moclobemide—Rash—Prednisolone—psoriasis	0.000181	0.000594	CcSEcCtD
Moclobemide—Dermatitis—Prednisolone—psoriasis	0.000181	0.000594	CcSEcCtD
Moclobemide—Fatigue—Prednisone—psoriasis	0.00018	0.000591	CcSEcCtD
Moclobemide—Headache—Prednisolone—psoriasis	0.00018	0.000591	CcSEcCtD
Moclobemide—Discomfort—Methotrexate—psoriasis	0.00018	0.00059	CcSEcCtD
Moclobemide—Constipation—Prednisone—psoriasis	0.000179	0.000586	CcSEcCtD
Moclobemide—Vomiting—Hydrocortisone—psoriasis	0.000179	0.000585	CcSEcCtD
Moclobemide—Rash—Hydrocortisone—psoriasis	0.000177	0.00058	CcSEcCtD
Moclobemide—Dermatitis—Hydrocortisone—psoriasis	0.000177	0.00058	CcSEcCtD
Moclobemide—Confusional state—Methotrexate—psoriasis	0.000176	0.000577	CcSEcCtD
Moclobemide—Headache—Hydrocortisone—psoriasis	0.000176	0.000577	CcSEcCtD
Moclobemide—Dizziness—Triamcinolone—psoriasis	0.000175	0.000573	CcSEcCtD
Moclobemide—Feeling abnormal—Prednisone—psoriasis	0.000172	0.000564	CcSEcCtD
Moclobemide—Asthenia—Dexamethasone—psoriasis	0.000172	0.000564	CcSEcCtD
Moclobemide—Asthenia—Betamethasone—psoriasis	0.000172	0.000564	CcSEcCtD
Moclobemide—MAOA—SIDS Susceptibility Pathways—IL13—psoriasis	0.000172	0.00779	CbGpPWpGaD
Moclobemide—Gastrointestinal pain—Prednisone—psoriasis	0.000171	0.00056	CcSEcCtD
Moclobemide—Nausea—Prednisolone—psoriasis	0.000171	0.00056	CcSEcCtD
Moclobemide—Pruritus—Dexamethasone—psoriasis	0.00017	0.000556	CcSEcCtD
Moclobemide—Pruritus—Betamethasone—psoriasis	0.00017	0.000556	CcSEcCtD
Moclobemide—Hyperhidrosis—Methotrexate—psoriasis	0.000169	0.000553	CcSEcCtD
Moclobemide—Vomiting—Triamcinolone—psoriasis	0.000168	0.000551	CcSEcCtD
Moclobemide—Nausea—Hydrocortisone—psoriasis	0.000167	0.000547	CcSEcCtD
Moclobemide—Rash—Triamcinolone—psoriasis	0.000167	0.000547	CcSEcCtD
Moclobemide—Dermatitis—Triamcinolone—psoriasis	0.000167	0.000546	CcSEcCtD
Moclobemide—Urticaria—Prednisone—psoriasis	0.000166	0.000544	CcSEcCtD
Moclobemide—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000166	0.00752	CbGpPWpGaD
Moclobemide—Headache—Triamcinolone—psoriasis	0.000166	0.000543	CcSEcCtD
Moclobemide—Abdominal pain—Prednisone—psoriasis	0.000165	0.000541	CcSEcCtD
Moclobemide—Diarrhoea—Dexamethasone—psoriasis	0.000164	0.000538	CcSEcCtD
Moclobemide—Diarrhoea—Betamethasone—psoriasis	0.000164	0.000538	CcSEcCtD
Moclobemide—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000163	0.00742	CbGpPWpGaD
Moclobemide—Hypotension—Methotrexate—psoriasis	0.000163	0.000535	CcSEcCtD
Moclobemide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000161	0.00731	CbGpPWpGaD
Moclobemide—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000161	0.00729	CbGpPWpGaD
Moclobemide—Musculoskeletal discomfort—Methotrexate—psoriasis	0.000159	0.000522	CcSEcCtD
Moclobemide—Dizziness—Dexamethasone—psoriasis	0.000159	0.00052	CcSEcCtD
Moclobemide—Dizziness—Betamethasone—psoriasis	0.000159	0.00052	CcSEcCtD
Moclobemide—Insomnia—Methotrexate—psoriasis	0.000158	0.000518	CcSEcCtD
Moclobemide—Nausea—Triamcinolone—psoriasis	0.000157	0.000515	CcSEcCtD
Moclobemide—Paraesthesia—Methotrexate—psoriasis	0.000157	0.000514	CcSEcCtD
Moclobemide—Dyspnoea—Methotrexate—psoriasis	0.000156	0.00051	CcSEcCtD
Moclobemide—Somnolence—Methotrexate—psoriasis	0.000155	0.000509	CcSEcCtD
Moclobemide—Dyspepsia—Methotrexate—psoriasis	0.000154	0.000504	CcSEcCtD
Moclobemide—Vomiting—Dexamethasone—psoriasis	0.000153	0.0005	CcSEcCtD
Moclobemide—Vomiting—Betamethasone—psoriasis	0.000153	0.0005	CcSEcCtD
Moclobemide—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000152	0.00692	CbGpPWpGaD
Moclobemide—Decreased appetite—Methotrexate—psoriasis	0.000152	0.000498	CcSEcCtD
Moclobemide—Rash—Dexamethasone—psoriasis	0.000151	0.000496	CcSEcCtD
Moclobemide—Rash—Betamethasone—psoriasis	0.000151	0.000496	CcSEcCtD
Moclobemide—Dermatitis—Dexamethasone—psoriasis	0.000151	0.000495	CcSEcCtD
Moclobemide—Dermatitis—Betamethasone—psoriasis	0.000151	0.000495	CcSEcCtD
Moclobemide—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000151	0.00686	CbGpPWpGaD
Moclobemide—Fatigue—Methotrexate—psoriasis	0.000151	0.000494	CcSEcCtD
Moclobemide—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.00015	0.00682	CbGpPWpGaD
Moclobemide—Headache—Dexamethasone—psoriasis	0.00015	0.000493	CcSEcCtD
Moclobemide—Headache—Betamethasone—psoriasis	0.00015	0.000493	CcSEcCtD
Moclobemide—Asthenia—Prednisone—psoriasis	0.00015	0.000491	CcSEcCtD
Moclobemide—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000149	0.00676	CbGpPWpGaD
Moclobemide—Pruritus—Prednisone—psoriasis	0.000148	0.000485	CcSEcCtD
Moclobemide—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000148	0.00671	CbGpPWpGaD
Moclobemide—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.000147	0.00667	CbGpPWpGaD
Moclobemide—Feeling abnormal—Methotrexate—psoriasis	0.000144	0.000472	CcSEcCtD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000144	0.00653	CbGpPWpGaD
Moclobemide—Diarrhoea—Prednisone—psoriasis	0.000143	0.000469	CcSEcCtD
Moclobemide—Gastrointestinal pain—Methotrexate—psoriasis	0.000143	0.000468	CcSEcCtD
Moclobemide—Nausea—Dexamethasone—psoriasis	0.000143	0.000467	CcSEcCtD
Moclobemide—Nausea—Betamethasone—psoriasis	0.000143	0.000467	CcSEcCtD
Moclobemide—Urticaria—Methotrexate—psoriasis	0.000139	0.000455	CcSEcCtD
Moclobemide—Dizziness—Prednisone—psoriasis	0.000138	0.000453	CcSEcCtD
Moclobemide—Abdominal pain—Methotrexate—psoriasis	0.000138	0.000453	CcSEcCtD
Moclobemide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000138	0.00625	CbGpPWpGaD
Moclobemide—Vomiting—Prednisone—psoriasis	0.000133	0.000436	CcSEcCtD
Moclobemide—Rash—Prednisone—psoriasis	0.000132	0.000432	CcSEcCtD
Moclobemide—Dermatitis—Prednisone—psoriasis	0.000132	0.000431	CcSEcCtD
Moclobemide—Headache—Prednisone—psoriasis	0.000131	0.000429	CcSEcCtD
Moclobemide—CYP1A2—Biological oxidations—CYP2S1—psoriasis	0.000129	0.00586	CbGpPWpGaD
Moclobemide—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	0.000127	0.00578	CbGpPWpGaD
Moclobemide—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	0.000127	0.00577	CbGpPWpGaD
Moclobemide—Asthenia—Methotrexate—psoriasis	0.000125	0.000411	CcSEcCtD
Moclobemide—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	0.000125	0.00568	CbGpPWpGaD
Moclobemide—Nausea—Prednisone—psoriasis	0.000124	0.000407	CcSEcCtD
Moclobemide—Pruritus—Methotrexate—psoriasis	0.000124	0.000405	CcSEcCtD
Moclobemide—Diarrhoea—Methotrexate—psoriasis	0.000119	0.000392	CcSEcCtD
Moclobemide—Dizziness—Methotrexate—psoriasis	0.000115	0.000379	CcSEcCtD
Moclobemide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000112	0.0051	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—NDUFA5—psoriasis	0.000112	0.00509	CbGpPWpGaD
Moclobemide—CYP1A2—Tryptophan metabolism—CAT—psoriasis	0.000111	0.00505	CbGpPWpGaD
Moclobemide—Vomiting—Methotrexate—psoriasis	0.000111	0.000364	CcSEcCtD
Moclobemide—Rash—Methotrexate—psoriasis	0.00011	0.000361	CcSEcCtD
Moclobemide—Dermatitis—Methotrexate—psoriasis	0.00011	0.000361	CcSEcCtD
Moclobemide—Headache—Methotrexate—psoriasis	0.000109	0.000359	CcSEcCtD
Moclobemide—MAOA—SIDS Susceptibility Pathways—IL10—psoriasis	0.000107	0.00487	CbGpPWpGaD
Moclobemide—Nausea—Methotrexate—psoriasis	0.000104	0.00034	CcSEcCtD
Moclobemide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	9.6e-05	0.00436	CbGpPWpGaD
Moclobemide—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	9.56e-05	0.00434	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—CYP2S1—psoriasis	9.54e-05	0.00433	CbGpPWpGaD
Moclobemide—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	8.79e-05	0.00399	CbGpPWpGaD
Moclobemide—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	7.45e-05	0.00338	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—NDUFA5—psoriasis	7.04e-05	0.00319	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	6.19e-05	0.00281	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—CYP2S1—psoriasis	5.99e-05	0.00272	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—CXCL8—psoriasis	5.87e-05	0.00266	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—JUN—psoriasis	5.46e-05	0.00248	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	5.35e-05	0.00243	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—NFKB1—psoriasis	5.25e-05	0.00238	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	5.15e-05	0.00234	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—VEGFA—psoriasis	4.77e-05	0.00216	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	4.67e-05	0.00212	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—CARM1—psoriasis	4.66e-05	0.00211	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—TNF—psoriasis	4.09e-05	0.00185	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	4e-05	0.00182	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	4e-05	0.00182	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—NDUFA5—psoriasis	3.33e-05	0.00151	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—IL6—psoriasis	3.3e-05	0.0015	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.11e-05	0.00141	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—NDUFA5—psoriasis	3.07e-05	0.00139	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—NDUFA5—psoriasis	3.04e-05	0.00138	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—CARM1—psoriasis	2.92e-05	0.00133	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—CAT—psoriasis	2.87e-05	0.0013	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—CYP2S1—psoriasis	2.83e-05	0.00129	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.83e-05	0.00129	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—CYP2S1—psoriasis	2.61e-05	0.00118	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—NDUFA5—psoriasis	2.6e-05	0.00118	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—CYP2S1—psoriasis	2.58e-05	0.00117	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.42e-05	0.0011	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—APOE—psoriasis	2.23e-05	0.00101	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—CYP2S1—psoriasis	2.21e-05	0.001	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—PPARG—psoriasis	1.94e-05	0.00088	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—CAT—psoriasis	1.8e-05	0.000816	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.49e-05	0.000674	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—APOE—psoriasis	1.4e-05	0.000634	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—CARM1—psoriasis	1.38e-05	0.000628	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.35e-05	0.000614	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.29e-05	0.000587	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—CARM1—psoriasis	1.27e-05	0.000578	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—CARM1—psoriasis	1.26e-05	0.000573	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—PPARG—psoriasis	1.22e-05	0.000552	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.18e-05	0.000535	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.16e-05	0.000525	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—CARM1—psoriasis	1.08e-05	0.000489	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.01e-05	0.000457	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—CAT—psoriasis	8.51e-06	0.000386	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—CAT—psoriasis	7.83e-06	0.000355	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—CAT—psoriasis	7.76e-06	0.000352	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—CAT—psoriasis	6.63e-06	0.000301	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—APOE—psoriasis	6.61e-06	0.0003	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—APOE—psoriasis	6.08e-06	0.000276	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—APOE—psoriasis	6.03e-06	0.000274	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—PPARG—psoriasis	5.76e-06	0.000261	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—PPARG—psoriasis	5.3e-06	0.00024	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—PPARG—psoriasis	5.25e-06	0.000238	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—APOE—psoriasis	5.15e-06	0.000234	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—PPARG—psoriasis	4.49e-06	0.000204	CbGpPWpGaD
